This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Janssen Pharmaceutica Nv, Sanofi. Active years: 2017-2026.
Company Filing History:
Years Active: 2017-2026
Title: Helgi Van De Velde: Innovator in Cancer Treatment
Introduction
Helgi Van De Velde is a notable inventor based in Retie, Belgium. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on improving patient outcomes by identifying biomarkers that can predict adverse neurological events in response to cancer therapies.
Latest Patents
Helgi holds a patent for "Biomarkers for assessing peripheral neuropathy response to cancer treatment." This invention provides methods for identifying patients at increased risk of developing adverse neurological events due to cancer treatment. The methods also include modifying the treatment regimen based on the presence or absence of biomarkers in the patient.
Career Highlights
Helgi is currently employed at Janssen Pharmaceutica NV, a leading pharmaceutical company known for its commitment to innovation in healthcare. His work at Janssen has allowed him to contribute to groundbreaking research that aims to enhance the safety and efficacy of cancer treatments.
Collaborations
Helgi has collaborated with talented professionals in his field, including Nadine Cohen and Reyna L. Favis. These collaborations have fostered a productive environment for innovation and have led to advancements in cancer treatment methodologies.
Conclusion
Helgi Van De Velde is a distinguished inventor whose work in identifying biomarkers for cancer treatment has the potential to significantly improve patient care. His contributions to the field exemplify the importance of innovation in healthcare.